Alyra Biotech is a privately owned early-stage biopharmaceutical company headquartered and incorporated in the State of South Australia.
Further information for investors is available upon enquiry.
The Cost of Chronic Pain in Women
The ultimate goal of Alyra Biotech Pty Ltd is to reduce pelvic pain and pain-related symptoms in women using intrauterine neuroimmune modulation. 1 in 5 women have a chronic pain condition, and chronic pain costs us all in absenteeism, health expenses and reduced quality of living.
These costs have been estimated at $140Billion in Australia, and $640Billion in the United States.
By reducing health costs to companies and individuals, and increasing workplace productivity and well-being, our products offer a financial dividend to all.
Market Potential
Alyra Biotech has already completed pre-clinical, cell receptor, human blood and end-user research. The next logical step is to demonstrate that modulation of the immune system within the uterus can reduce pain in women. In 2023, Alyra Biotech will undertake first-in-human studies of our lead device.
We anticipate that this device will confirm that adding an immune inhibitor to a levonorgestrel-releasing intrauterine device (LNG-IUD) can reduce the pain experienced by women in the 3 months following insertion of commonly used LNG-IUDs. Pain post insertion is reported as a concern by 7.3% of women from the general community or 40% of women with pre-existing dysmenorrhoea following LNG-IUD insertion.
LNG-IUD devices are globally established contraceptives, with governments financially supporting their use and professional bodies driving uptake. By reducing the pain experienced by a proportion of women following device insertion we wish to enhance globally successful intrauterine devices.
In the US alone, there are 75 Million women aged 15 to 50, of which 15% use an IUD.
With a worldwide trend towards these devices, this market is estimated to grow by 8% per year.
Our focus group and consumer end-user research confirmed the strong interest, and preparedness to pay a premium for our product among typical end-users.
Our health practitioner end-user research confirmed the concerns health practitioners have with pain following intrauterine device insertion and the strong interest in the Alyra Device.
Regulatory authorities will welcome a device suited to reducing the Opioid Epidemic in western countries.
Pipeline Products
Building on innovative in-house research, Alyra Biotech is developing a platform of devices to address a range of women’s health conditions with devices tailored to their individual needs.
These additional pipeline products are focused both on both high-value targets, and on issues of importance to women in developing countries and low resource settings.
Partnering with Alyra Biotech
Alyra Biotech welcomes discussions with potential business partners who are aligned with our mission, and bring with them financial and thought capital resources.
Everyone gains when women have less pain.
For further information on investment opportunity
in Alyra Biotech, please contact the CEO Dr Susan Evans
